Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89.6M
-
Number of holders
-
91
-
Total 13F shares, excl. options
-
46.6M
-
Shares change
-
+1.48M
-
Total reported value, excl. options
-
$1.06B
-
Value change
-
+$20M
-
Put/Call ratio
-
4.42
-
Number of buys
-
56
-
Number of sells
-
-39
-
Price
-
$22.82
Significant Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q1 2022
112 filings reported holding VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2022.
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) has 91 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46.6M shares
of 89.6M outstanding shares and own 52.05% of the company stock.
Largest 10 shareholders include Alphabet Inc. (11M shares), FMR LLC (5.12M shares), Casdin Capital, LLC (3.14M shares), STATE STREET CORP (2.66M shares), ARCH Venture Management, LLC (2.51M shares), WELLINGTON MANAGEMENT GROUP LLP (2.35M shares), VANGUARD GROUP INC (2.32M shares), BlackRock Inc. (2.16M shares), Redmile Group, LLC (1.84M shares), and ARK Investment Management LLC (1.69M shares).
This table shows the top 91 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.